Pharmacokinetic Study and Bioequivalence Evaluation of Two Sustained‐Release Tablets of Tamsulosin in Healthy Chinese Subjects Under Fasting and Postprandial Conditions

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Randomized trial evaluated bioequivalence and pharmacokinetics of tamsulosin tablets, indicating safety and efficacy.

The study found that both formulations of tamsulosin were bioequivalent under fasting and postprandial conditions.
Confidence intervals for Cmax and AUC0-t were within the required range of 80%-125%, confirming acceptable bioequivalence.
A total of 56 healthy volunteers participated in the trial, which utilized a double-crossover design to assess pharmacokinetics.
All adverse events were mild, affirming the safety and tolerability of the tamsulosin sustained-release tablets.

Wang et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark